Marketing
-
Fintan Trimble via Getty Images
Generic drugmakers gain key victory in ‘skinny label’ patent case
The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.
By Jonathan Gardner • June 5, 2026 -
Scott Olson via Getty Images
Eli Lilly issues data sharing ultimatum to 340B hospitals
Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which have until Monday to comply, are urging the government to intervene.
By Rebecca Pifer Parduhn • June 2, 2026 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
Courtesy of Eli Lilly
Obesity drugsCVS obesity drug deal puts Lilly on equal footing with Novo
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
By Kristin Jensen • May 28, 2026 -
Courtesy of Eli Lilly
FDA asks Lilly to evaluate obesity pill’s liver risk
The request, which is part of a just-released approval letter for Foundayo, comes amid an intensifying marketing battle between Lilly and Novo.
By Jonathan Gardner • April 15, 2026 -
Mario Tama via Getty Images
J&J leans on Tremfya, cancer drugs to overcome Stelara losses
A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street’s expectations and surpass $15 billion in first-quarter drug sales.
By Jonathan Gardner • April 14, 2026 -
Courtesy of Eli Lilly
Obesity drugs
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk
After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.
By Kristin Jensen • April 9, 2026 -
Courtesy of Hims & Hers
Hims & Hers says limited data stolen in social engineering attack
The telehealth provider said hackers gained access to a third-party customer service platform, but medical records remained secure.
By David Jones • April 6, 2026 -
Scott Olson via Getty Images
Obesity drugs
FDA approves Lilly obesity pill, triggering battle with Novo Nordisk
Foundayo could erase the Wegovy pill’s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.
By Jonathan Gardner • April 1, 2026 -
Andrew Harnik via Getty Images
New FDA guidance could elevate pharma’s biosimilar market
Biologic copycats have had a limited impact on U.S. drug prices so far, but loosening regulatory restrictions could help accelerate their progress.
By Michael Gibney • March 13, 2026 -
Scott Olson via Getty Images
Obesity drugs
Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders
Lilly asked the FDA to step in after claiming that testing it’s done suggests copycat versions of Zepbound may carry “unknown risks.”
By Jonathan Gardner • March 12, 2026 -
Sarah Silbiger via Getty Images
Trump administrationFDA clears repurposed GSK drug for ultra-rare brain disease instead of autism
Months after promising help for “hundreds of thousands of kids,” the FDA approved the decades-old medicine for a disease documented in less than 50 people.
By Kristin Jensen • March 11, 2026 -
Courtesy of Hims & Hers
Obesity drugs
Novo, Hims reach deal to sell GLP-1 drugs together
The agreement ends a messy dispute that began when the telehealth firm attempted to sell a compounded form of Novo’s Wegovy pill at a cheaper price.
By Ben Fidler • March 9, 2026 -
Getty Images
FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo
The regimen’s clearance in early multiple myeloma was the third approval under the agency’s controversial “national priority” voucher program and issued only 55 days after the review began.
By Jonathan Gardner • March 6, 2026 -
Scott Olson via Getty Images
Obesity drugsLilly targets employers in new bid to broaden access to obesity drugs
A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot.
By Jonathan Gardner • March 5, 2026 -
Getty Images
Obesity drugsLilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial
Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.
By Jonathan Gardner • Feb. 26, 2026 -
Elijah Nouvelage via Getty Images
Vaccines15 states sue HHS over changes to childhood vaccine schedule
The lawsuit seeks to reverse the abrupt overhaul of the U.S. immunization schedule as well as the federal government’s allegedly “unlawful” reformation of a key vaccine panel.
By Delilah Alvarado • Feb. 25, 2026 -
Permission granted by Vertex
Vertex’s CRISPR therapy rebounds in latest earnings
Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.
By Gwendolyn Wu • Feb. 13, 2026 -
Permission granted by Gilead Sciences
Gilead dips as ‘strong’ earnings outweighed by high expectations for new HIV drug
Shares fell as much as 6% in after-hours trading, a decline one analyst guessed may be because Yeztugo’s trajectory isn’t matching investors’ sky-high hopes.
By Jacob Bell • Feb. 10, 2026 -
Spencer Platt via Getty Images
News roundupEarnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game
Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.
By BioPharma Dive staff • Feb. 5, 2026 -
Courtesy of Hims & Hers
Obesity drugs
Novo, Lilly sputter as Hims launches knockoff GLP-1 pill
Novo is threatening litigation in response, while FDA head Martin Makary, without naming specific companies, said the agency would take “swift action” against those “mass-marketing illegal copycat drugs.”
By Ben Fidler • Updated Feb. 6, 2026 -
Leigh Vogel via Getty Images
Express Scripts reaches ‘landmark’ settlement with FTC in insulin suit
The agreement announced Wednesday includes sweeping changes to the Cigna PBM’s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and reshoring its controversial rebate aggregator.
By Rebecca Pifer Parduhn • Updated Feb. 4, 2026 -
Win McNamee via Getty Images
Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.
By Emily Olsen • Feb. 4, 2026 -
Permission granted by Novo Nordisk
Novo shares tumble by double digits on grim sales outlook
In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits.
By Jonathan Gardner • Feb. 4, 2026 -
Scott Olson via Getty Images
Obesity drugs
Lilly soars again as fast-selling weight loss drugs top Wall Street projections
Despite some angst over pricing pressure for GLP-1 drugs, Lilly’s bullish projections surpassed consensus estimates, while combined 2025 sales of Zepbound and Mounjaro eclipsed $36 billion.
By Kristin Jensen • Feb. 4, 2026 -
Getty Images
News roundupEarnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan
Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.
By BioPharma Dive staff • Feb. 4, 2026
